Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Colorcon
Daiichi Sankyo
UBS
QuintilesIMS
US Army
Teva
Julphar
Accenture

Generated: October 21, 2018

DrugPatentWatch Database Preview

TRILIPIX Drug Profile

« Back to Dashboard

When do Trilipix patents expire, and when can generic versions of Trilipix launch?

Trilipix is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.

Drug patent expirations by year for TRILIPIX
Pharmacology for TRILIPIX
Synonyms for TRILIPIX
1034151-05-7
2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid choline salt
2-Hydroxy-N,N,N-trimethylethanaminium 2-(-(4-chlorobenzoyl)phenoxy)-2- methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
2-Hydroxy-N,N,N-trimethylethanaminium2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate
3320AC
4BMH7IZT98
856676-23-8
ABT 335
ABT-335
AK119697
AKOS016010592
API0009427
AS-10210
AX8245113
CHEMBL1201745
Choline fenofibrate
Choline fenofibrate (ABT-335)
Choline fenofibrate (USAN/INN)
Choline fenofibrate [USAN:INN]
CS-0893
CTK8E8257
D01HKL
D08890
DTXSID50234939
Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 2-(4-(4- chlorobenzoyl)phenoxy)-2-methylpropanoic acid (1:1)
Fenofibrate de choline
Fenofibric acid (TN)
FT-0665026
HIP0901
HY-14739
JWAZHODZSADEHB-UHFFFAOYSA-M
KS-00000R22
MolPort-006-393-282
OR352514
RT-012006
ST24040685
UNII-4BMH7IZT98
W-5743

US Patents and Regulatory Information for TRILIPIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-001 Dec 15, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TRILIPIX
Drugname Dosage Strength RLD Date
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for TRILIPIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0907 Netherlands ➤ Sign Up PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT
2017 00030 Denmark ➤ Sign Up PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
C0009 Belgium ➤ Sign Up PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Colorcon
Daiichi Sankyo
UBS
QuintilesIMS
US Army
Teva
Julphar
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.